The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Stolichnaya makes a ginger beer and is considering tonic water and club soda. https://www.nytimes.com/2017/02/06/dining/liquor-companies-add-mixers-to-products.html?_r=0
It's worth checking the advfn chat forums from time to time - there's usually a bearish case presented there (something often lacking from lse) as well as the bull case, so could provide better general idea about when to sell and take profit.
"The rivals have benefited from the renaissance of gin, whose sales are surging as hip, young distillers breathe new life into it." My last post for today, and apologies for being so bearish, but when will the "hip, young distillers" turn their attention to making their own premium tonics for their gins?
http://www.thisismoney.co.uk/money/markets/article-4193772/Fentimans-prepares-Fever-Tree-mixers.html The battle for Britain’s poshest tonic is fizzing up as Fentimans prepares to take on Fever-Tree with a range of upmarket mixers. Fentimans, which is best known for botanical soft drinks such as ginger beer and cola, is making a £1m investment in production to boost sales of mixers for alcoholic drinks. The firm wants its tonic water and other mixers to account for 40 per cent of sales by 2020. The news will worry Fever-Tree, which has had the upmarket mixer category largely to itself. Read more: http://www.thisismoney.co.uk/money/markets/article-4193772/Fentimans-prepares-Fever-Tree-mixers.html#ixzz4XtrLfWQx Follow us: @MailOnline on Twitter | DailyMail on Facebook
As I predicted... The battle for Britain’s poshest tonic is fizzing up as Fentimans prepares to take on Fever-Tree with a range of upmarket mixers, reports the Mail. http://www.proactiveinvestors.co.uk/companies/market_reports/172681/ftse-100-edges-lower-seeking-fresh-direction
Standard Chartered PLC (LON:STAN) remains a sell for the analysts at Deutsche Bank, even though they have upped their target price on the Asia-focused bank. Indeed, even with the share price upgrade, the broker still sees 24% potential downside following the substantial share price outperformance this year against the major share indices. This is unjustified, reckons Deutsche Bank. Standard Chartered may be geared to higher US rates, but higher revenues are already in the price and the market’s view on cost reductions is too bullish. Deutsche has nudged up its target price by 45p to 600p, but the rating remains ‘sell' even with the outside chance of a bid.
a technical trade based on the high RSI (now 86 I believe). It's an excellent tonic water but remember there are other players hot on their heels - BTW (Bermondsey Tonic Water) looks interesting. I would disagree that barriers to entry are high - low barrier to entry is one reason for FEVR's success up to now.